The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Expected Market Value Outlook For The Neupogen (filgrastim) Market Through 2030?
The neupogen (filgrastim) market size has experienced robust growth in recent years. It is projected to expand from $1.4 million in 2025 to $1.48 million in 2026, demonstrating a compound annual growth rate (CAGR) of 5.5%. The expansion witnessed during the historic period stems from increased chemotherapy utilization, the elevated risk of infection among neutropenic patients, the clinical validation of g-csf therapy, hospital-focused cancer care models, and limited early treatment alternatives.
The neupogen (filgrastim) market is anticipated to show significant expansion in the upcoming years. Its valuation is projected to reach $1.81 million by 2030, demonstrating a compound annual growth rate (CAGR) of 5.2%. The growth during the forecast period stems from factors such as increasing cancer incidence, a broader adoption of biosimilars, the expansion of outpatient oncology services, enhanced access to biologic therapies, and a strong emphasis on infection prevention. Key trends expected over the forecast period include the rising application of supportive care in oncology, the expansion of management strategies for chemotherapy-induced neutropenia, increased uptake of biologic growth factors, a shift towards outpatient treatment for neutropenia, and the growing utilization of biosimilar alternatives.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19910&type=smp
What Market Drivers Are Helping Shape The Neupogen (filgrastim) Market Expansion?
The neupogen (filgrastim) market is anticipated to expand due to the growing occurrence of diverse illnesses. Illnesses represent dysfunctions or structural irregularities within the body, manifesting distinct symptoms or impacting particular areas, frequently stemming from infections, genetic predispositions, environmental influences, or lifestyle choices. This surge in disease prevalence is fueled by an aging global populace, inactive lifestyles, heightened pollution, inadequate nutritional practices, and the worldwide dissemination of infectious agents. Neupogen (filgrastim) helps manage issues arising from chemotherapy-induced neutropenia by stimulating neutrophil generation, thus bolstering the immune system’s capacity to fight off infections in individuals with compromised immunity. Its role is crucial in lowering hospital admissions, mitigating infection dangers, and ensuring continuous cancer therapy for patients undergoing demanding treatments. For example, data from Allergy UK, a UK-based national charity, revealed in April 2024 that over 21 million people in the UK suffer from allergies, which was identified as the most common chronic health condition in 2022. Forecasts suggest that by 2026, half of Europe’s population will experience at least one allergy. Furthermore, in June 2022, Macmillan Cancer Support, a UK-based cancer charity, reported that 3 million individuals were living with cancer in the UK, a number expected to grow to nearly 3.5 million by 2025 and 4 million by 2030. Consequently, the rising incidence of diverse illnesses is fueling the expansion of the neupogen (filgrastim) market.
How Is The Neupogen (filgrastim) Market Distributed Across Key Segments?
The neupogen (filgrastim) market covered in this report is segmented –
1) By Drug Type: Biologic, Biosimilar
2) By Indication: Chemotherapy Induced Neutropenia, Chronic Neutropenia, Others
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Which Trends Are Expected To Shape The Neupogen (filgrastim) Market?
Companies operating primarily in the neupogen (filgrastim) market are increasingly concentrating on the development of novel filgrastim biosimilar products, aiming to offer an economical and accessible solution for managing chemotherapy-induced neutropenia. These filgrastim biosimilars are biological medicines designed to closely mirror the original filgrastim (Neupogen) in terms of safety, effectiveness, and molecular structure. Their primary function is to stimulate the creation of neutrophils in patients undergoing chemotherapy, thereby preventing neutropenia. For example, in September 2024, Tanvex BioPharma, a U.S.-based biopharmaceutical entity, secured approval from the U.S. Food and Drug Administration (FDA) for Nypozi (filgrastim-txid), a biosimilar that references Amgen’s Neupogen. Nypozi was one of three biosimilars that received FDA clearance on that specific day, contributing to a cumulative total of 55 biosimilars approved in the United States by June 2024. This drug is prescribed to lessen the frequency of infection, particularly as it manifests in febrile neutropenia, for patients with non-myeloid malignancies receiving myelosuppressive anticancer agents.
Which Companies Form The Competitive Landscape Of The Neupogen (filgrastim) Market?
Major companies operating in the neupogen (filgrastim) market are Amgen Inc.
Access The Complete Neupogen (filgrastim) Market Report:
https://www.thebusinessresearchcompany.com/report/neupogen-filgrastim-global-market-report-
Which Regional Market Leads The Neupogen (filgrastim) Market?
North America was the largest region in the neupogen (filgrastim) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model